MX2020010618A - Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. - Google Patents
Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.Info
- Publication number
- MX2020010618A MX2020010618A MX2020010618A MX2020010618A MX2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A MX 2020010618 A MX2020010618 A MX 2020010618A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonist
- pyrazolotriazolopyrimidine
- derivatives
- pyrazolotriazolopyrimidine derivatives
- stereoisomer
- Prior art date
Links
- 229940127600 A2A receptor antagonist Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018082140 | 2018-04-08 | ||
| PCT/CN2019/081785 WO2019196803A1 (en) | 2018-04-08 | 2019-04-08 | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010618A true MX2020010618A (es) | 2020-11-12 |
Family
ID=68163465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010618A MX2020010618A (es) | 2018-04-08 | 2019-04-08 | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11472811B2 (enExample) |
| EP (1) | EP3774813A4 (enExample) |
| JP (1) | JP2021520392A (enExample) |
| KR (1) | KR20200140849A (enExample) |
| CN (1) | CN112313234B (enExample) |
| AU (1) | AU2019251148A1 (enExample) |
| BR (1) | BR112020020078A2 (enExample) |
| CA (1) | CA3095839A1 (enExample) |
| EA (1) | EA202092036A1 (enExample) |
| IL (1) | IL277744A (enExample) |
| MX (1) | MX2020010618A (enExample) |
| SG (1) | SG11202009706VA (enExample) |
| TW (1) | TW202010500A (enExample) |
| WO (1) | WO2019196803A1 (enExample) |
| ZA (1) | ZA202005772B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200140849A (ko) | 2018-04-08 | 2020-12-16 | 베이진 엘티디 | A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체 |
| WO2021191376A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
| US12552799B2 (en) | 2020-03-26 | 2026-02-17 | Nxera Pharma Uk Limited | Triazolone compounds |
| WO2022087146A1 (en) | 2020-10-22 | 2022-04-28 | Landos Biopharma, Inc. | Lancl ligands |
| CN113773327B (zh) * | 2021-09-13 | 2022-07-15 | 八叶草健康产业研究院(厦门)有限公司 | 一种吡唑并嘧啶并三唑环类化合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1283839E (pt) | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| BR0213172A (pt) | 2001-10-08 | 2004-09-14 | Hoffmann La Roche | Amida do ácido 8-amino-[1,2,4]triazolo[1,5-a]piridina-6-carboxìlico |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| ATE461932T1 (de) | 2004-04-21 | 2010-04-15 | Schering Corp | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors |
| CN103261202B (zh) | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2017136375A1 (en) | 2016-02-05 | 2017-08-10 | Concert Pharmaceuticals, Inc. | Deuterated tozadenant |
| KR20200140849A (ko) | 2018-04-08 | 2020-12-16 | 베이진 엘티디 | A2a 수용체 길항제로서의 피라졸로트리아졸로피리미딘 유도체 |
| CN110742893B (zh) | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
-
2019
- 2019-04-08 KR KR1020207031434A patent/KR20200140849A/ko not_active Ceased
- 2019-04-08 TW TW108112189A patent/TW202010500A/zh unknown
- 2019-04-08 WO PCT/CN2019/081785 patent/WO2019196803A1/en not_active Ceased
- 2019-04-08 EP EP19785064.7A patent/EP3774813A4/en not_active Withdrawn
- 2019-04-08 AU AU2019251148A patent/AU2019251148A1/en not_active Abandoned
- 2019-04-08 MX MX2020010618A patent/MX2020010618A/es unknown
- 2019-04-08 CN CN201980024422.3A patent/CN112313234B/zh not_active Expired - Fee Related
- 2019-04-08 CA CA3095839A patent/CA3095839A1/en active Pending
- 2019-04-08 EA EA202092036A patent/EA202092036A1/ru unknown
- 2019-04-08 JP JP2020554834A patent/JP2021520392A/ja not_active Withdrawn
- 2019-04-08 US US16/982,681 patent/US11472811B2/en active Active
- 2019-04-08 BR BR112020020078-6A patent/BR112020020078A2/pt not_active IP Right Cessation
- 2019-04-08 SG SG11202009706VA patent/SG11202009706VA/en unknown
-
2020
- 2020-09-17 ZA ZA2020/05772A patent/ZA202005772B/en unknown
- 2020-10-01 IL IL277744A patent/IL277744A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020020078A2 (pt) | 2021-01-05 |
| WO2019196803A1 (en) | 2019-10-17 |
| SG11202009706VA (en) | 2020-10-29 |
| CN112313234A (zh) | 2021-02-02 |
| EA202092036A1 (ru) | 2021-01-28 |
| ZA202005772B (en) | 2022-01-26 |
| US20210198267A1 (en) | 2021-07-01 |
| IL277744A (en) | 2020-11-30 |
| US11472811B2 (en) | 2022-10-18 |
| AU2019251148A1 (en) | 2020-10-22 |
| CA3095839A1 (en) | 2019-10-17 |
| JP2021520392A (ja) | 2021-08-19 |
| TW202010500A (zh) | 2020-03-16 |
| CN112313234B (zh) | 2022-04-29 |
| EP3774813A1 (en) | 2021-02-17 |
| EP3774813A4 (en) | 2021-11-17 |
| KR20200140849A (ko) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124669T1 (el) | ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY | |
| MX2023008954A (es) | Inhibidores de los receptores erbb. | |
| MY174821A (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| PH12019501639A1 (en) | Jaki selective inhibitors | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| SA519401336B1 (ar) | تركيبة صيدلية | |
| EA202092036A1 (ru) | Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a | |
| TR201903322T4 (tr) | Kinaz inhibisyonu için heteroaril bileşikleri. | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| SA520411635B1 (ar) | A2a مشتق حلقي مدمج كمثبط مستقبل | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| MX2020007062A (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| AU2017257755A1 (en) | Benzoylglycine derivatives and methods of making and using same | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| MX379576B (es) | Derivados de azetidina | |
| AU2017264839A1 (en) | 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
| BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona |